We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

9945:TWSERuentex Development Co., Ltd. Analysis

Data as of 2026-06-18 - not real-time

NT$27.50

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Ruentex Development appears markedly undervalued – the market price of TWD 27.5 sits well below the DCF‑derived fair value of roughly TWD 30.5 and the sector’s average PE of over 30, while its own trailing PE hovers around 7. Revenue is accelerating at a 25% annual rate, and profit margins are robust, delivering a 36% net margin. However, the balance sheet shows a sizable debt load (over TWD 64 billion) and negative free cash flow, indicating that cash generation remains a concern. No dividend is paid, so income‑focused investors have little appeal here.
On the technical side, the stock is perched near its recent resistance around TWD 27.9, with the 20‑day SMA (≈24.97) still below price, suggesting limited upside in the very short run. RSI is elevated at 73, flagging overbought conditions, yet the MACD is bullish and volume is rising, hinting at lingering momentum. Volatility is high at roughly 27% over the past month, but beta is low (≈0.32), meaning broader market swings have muted impact. Overall, the blend of strong fundamentals and attractive valuation supports a positive outlook, while short‑term price pressure advises caution.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI in overbought territory
  • Price near resistance level
  • Neutral trend despite bullish MACD

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued relative to DCF and industry PE
  • Strong revenue growth (≈25%)
  • Low beta with improving technical momentum

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Sustainable high profit margin
  • Strategic positioning in construction and real estate
  • Solid earnings base despite high debt

Key Metrics & Analysis

Financial Health

Revenue Growth25.50%
Profit Margin36.41%
P/E Ratio7.0
ROE15.35%
ROA2.32%
Debt/Equity52.72
P/B Ratio0.5
Op. Cash FlowNT$5.8B
Free Cash FlowNT$-7804571648
Industry P/E31.4

Technical Analysis

TrendNeutral
RSI73.3
SupportNT$22.90
ResistanceNT$27.90
MA 20NT$24.97
MA 50NT$24.44
MA 200NT$28.04
MACDBullish
VolumeIncreasing
Fear & Greed Index92.09

Valuation

Fair ValueNT$30.48
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.32
Volatility26.69%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.